PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

Lilly’s mirikizumab hits primary endpoint in ulcerative colitis study

Eli Lilly’s anti-IL-23p19 monoclonal antibody (mAb) mirikizumab has met the primary endpoint and all key secondary endpoints in a Phase III ulcerative colitis (UC) study.
The 12-week LUCENT-1 induction study evaluated mirikizumab for the treatment of patients with moderate to severe UC.
UC is a chronic and often debilitating inflammatory disease of the large intestine that affects millions of people globally.
Symptoms of UC can include chronic diarrhoea with blood and mucus, abdominal pain and cramping, and weight loss. UC can have a significant effect on work, family and social activities.
In LUCENT-1, mirikizumab hit the primary endpoint of clinical remission at week 12 compared to placebo. This means that inflammation of the colon is controlled or resolved, leading to normalisation or near-normalisation of symptoms.
In addition, mirikizumab met all key secondary endpoints in patients with UC at week 12, with ‘highly statistically significant’ p-values.
This included reduced bowel urgency, clinical response, endoscopic remission, symptomatic remission and improvement in endoscopic histologic inflammation.
Mirikizumab also demonstrated rapid improvement in patient symptoms as early as four weeks after initiating treatment, and reduced symptoms among patients who had previously not responded or had stopped responding to biologic or Janus kinase (JAK) inhibitor therapies.
“People living with UC often struggle to effectively manage recurring flare ups of the disease,” said Lotus Mallbris, vice president of immunology development at Lilly.
“With these positive results, we look forward to the continuation of the maintenance study through 52 weeks in hopes of providing a new option to people living with UC,” she added.

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026